Cassandra Strickland Kennedy has served as Chief Quality, Regulatory Affairs, and Sustainability Officer since May 2023 with oversight of Global Regulatory Compliance, Quality Assurance and Environmental, Social and Governance at Fortrea. 

Sandy brings more than three decades of biopharmaceutical industry experience, with a long track record of success in leadership positions within the pharmaceutical and CRO environments. She served as Senior Vice President of Global Regulatory Compliance & Quality Assurance at Labcorp Drug Development from 2018 to 2023, prior to Fortrea’s spinoff from Labcorp. Previously, Sandy was Senior Vice President, Global Compliance & Quality with Quintiles, now part of IQVIA, where she was employed for 20 years. In this position, she was a member of the Enterprise Compliance Office and the Compliance Management Committee of Quintiles. Sandy was a founding member of the Quintiles Data Privacy Board and served as Vice-Chairman of the Ethics Board. Before joining Quintiles in 1997, she was US Quality Assurance Manager at Parexel International. Sandy began her career at Solvay Pharmaceuticals in Research & Development from 1987 to 1994. 

Sandy earned her bachelor's degree in Clinical Psychology from Lipscomb University and is certified in Regulatory Affairs and Healthcare Compliance. She has served on a number of industry associations, including 2022 and 2023 Secretary of Association of Contract Research Organizations (ACRO) and as co-chair of the ACRO Forum with TransCelerate. In addition to her industry leadership role, she has demonstrated her passion for developing and advancing women. She was a founding member and board chair of the Quintiles Women Inspired Network and a member of the Advisory Team at Labcorp’s Women in Leadership. Sandy served on the RTP Board of Directors for the non-profit organization Dress for Success, which works to empower women to achieve economic independence and thrive in work and in life.

Alejandro Martinez-Galindo is Chief Information Officer, leading Fortrea’s information technology vision and strategy to enable life-changing research and solutions. Alejandro joined the organization in May 2023 during Fortrea’s spinoff from its parent company, Labcorp. 

Alejandro is a global technology leader with more than 30 years of experience in the healthcare, life sciences, retail, supply chain, manufacturing and automotive sectors. Most recently, he was the Chief Information Officer of Capri Holdings, a luxury fashion retailer. Previously, Alejandro served as the Walgreens Boots Alliance (WBA) Chief Information Officer, where he led a comprehensive transformation of the company’s retail digital platform. Prior to WBA, he was Chief Information Officer at Quintiles, now part of IQVIA. Earlier in his career, he held multiple Chief Information Officer roles at General Motors, where he lived and worked in LATAM, EMEA and North America, including Chief Information Officer of Europe, based in London. Before joining General Motors, he was information technology and strategic planning director at PACCAR Mexico, responsible for IT operations of four business units in Mexico, including Kenworth Mexicana, PACCAR Capital Mexico, PacLease Mexicana and PACCAR Parts Mexico. 

Martinez received a bachelor's degree in Computer Sciences and earned a master's degree from La Salle University, Mexico City. He also has a manufacturing systems degree from ITESM, Mexico and a business degree from UIA, Mexico. Alejandro was part of the GM Senior Executive program and attended several executive programs at the MIT and University of Oxford, Saïd Business School.

Zehra Nurgul Pamuklar, MD, PhD, is a Senior Medical Director of Oncology for Fortrea, based in Cary, North Carolina. Dr. Pamuklar has more than 20 years of experience in oncology clinical drug development in biotechnology companies and CROs. She has supported planning and execution of global oncology clinical development projects from early phase to post approval, within medical affairs and clinical development organizations, and management of pharmaceutical, academic and regulatory interactions. 

Dr. Pamuklar graduated in medicine from the Ankara University School of Medicine, Ankara, Turkey; she has a PhD in Physiology/Immunophysiology and a Master of Science Degree in Clinical Research Management from Duke University, Durham, NC. 

Before joining our company in 2019, Dr. Pamuklar provided medical management of Phase I to Phase III immuno-oncology/oncology clinical trials in non-small cell lung cancer, hepatocellular carcinoma, bladder cancer, esophageal carcinoma, melanoma, pancreatic cancer, prostate cancer, urothelial cancer, colorectal cancer and head and neck cancer.

Yulianna Tymovska, MD, PhD, is Senior Medical Director based in Brisbane, Australia. Dr. Tymovska has 20 years of clinical experience, specializing in Oncology (extensive clinical experience in breast, head and neck cancer, melanoma, and gynecology malignancies diagnostic and treatment, as well as research in mechanisms of tumors resistance to anti-cancer treatment and immune oncology). 

Dr. Tymovska has more than 15 years of clinical research experience as a clinical trial investigator and medical director (monitor) providing medical expert oversight and monitoring of clinical trials, contribution and scientific expertise to study design, and regulatory documents, work in cross functional team on all phases of the studies and trials including feasibility assessments, design process, education efforts, and management of medical information. 

Dr. Tymovska earned her medical degree and completed clinical oncology postgraduate training in Bogomolets National Medical University, Kyiv, Ukraine, and PhD training in Kavetsky IEPOR of NAS of Ukraine. She joined our company in Jan 2023.

As a member of our global team of Medical Monitors, Dr. Yi Pi has significant medical and pharmaceutical expertise with more than 15 years in the industry and academia. He was certificated for specialized clinical practice in Cardiac Surgery and internal Medicine of Cardiology and had performed as the Principal Investigator and Medical Monitor, fully engaged in both designing and implementing clinical research in China National Center for Cardiovascular Diseases, Fuwai hospital and Duke Clinical Research Institute. 

After joining our company in 2021, Dr. Pi has been working as lead/regional physician on multiply early phase studies, as well as confirmatory trials in treatment areas including Oncology, as well as Cardiology, Endocrinology, Respirology, Neurology, Dermatology and Rare Diseases. Dr. Pi earned his medical degree from Xiangya School of Medicine and Master of Health Science degree from Duke University School of Medicine.